
Brain-cell penetrating antibodies for treatment of progressive multiple sclerosisAward last edited on: 3/26/2022
Sponsored Program
SBIRAwarding Agency
NIH : NINDSTotal Award Amount
$399,107Award Phase
1Solicitation Topic Code
853Principal Investigator
Hiep T TranCompany Information
Abzyme Therapeutics LLC
321 Jones Boulevard Suite 300
Royersford, PA 19468
Royersford, PA 19468
(610) 990-7531 |
info@abzymetx.com |
www.abzymetx.com |
Location: Single
Congr. District: 04
County: Montgomery
Congr. District: 04
County: Montgomery
Phase I
Contract Number: 1R43NS120624-01A1Start Date: 9/15/2021 Completed: 8/31/2022
Phase I year
2021Phase I Amount
$399,107Public Health Relevance Statement:
Narrative: As result of this project, first in class complement inhibiting and neurotropic antibody therapeutics capable of crossing the blood brain barrier for treatment of progressive multiple sclerosis will be obtained.
Project Terms:
Adult ; 21+ years old ; Adult Human ; adulthood ; Age ; ages ; Amino Acids ; aminoacid ; Animals ; Antibodies ; Bacterial Infections ; bacteria infection ; bacterial disease ; Biological Assay ; Assay ; Bioassay ; Biologic Assays ; Blood ; Blood Reticuloendothelial System ; Blood - brain barrier anatomy ; Blood-Brain Barrier ; Hemato-Encephalic Barrier ; bloodbrain barrier ; Brain ; Brain Nervous System ; Encephalon ; Cell Culture Techniques ; cell culture ; Cells ; Cell Body ; Central Nervous System Diseases ; CNS Diseases ; CNS disorder ; Central Nervous System Disorders ; Complement ; Complement Proteins ; Complement 1q ; C1 q ; C1q ; Complement C1q ; Complement Activation ; complement pathway regulation ; Complement Inactivators ; Complement Inhibitors ; Demyelinating Diseases ; Demyelinating Disorders ; Disease ; Disorder ; Engineering ; Exhibits ; Eye diseases ; eye disorder ; ophthalmopathy ; Foundations ; Goals ; Growth ; Generalized Growth ; Tissue Growth ; ontogeny ; Hemolysis ; erythrolysis ; Human ; Modern Man ; In Vitro ; Infection ; Intraperitoneal Injections ; IP injection ; Japanese Population ; Japanese ; Multiple Sclerosis ; Disseminated Sclerosis ; insular sclerosis ; Mus ; Mice ; Mice Mammals ; Murine ; Nerve ; Nerve Degeneration ; Neuron Degeneration ; neural degeneration ; neurodegeneration ; neurodegenerative ; neurological degeneration ; neuronal degeneration ; Ophthalmology ; Pathology ; Patients ; Peptides ; Play ; Production ; Proteins ; Thrombotic Thrombocytopenic Purpura ; Moschkowitz Disease ; Thrombotic Thrombopenic Purpura ; Rabies virus ; Role ; social role ; medical schools ; medical college ; school of medicine ; Signal Transduction ; Cell Communication and Signaling ; Cell Signaling ; Intracellular Communication and Signaling ; Signal Transduction Systems ; Signaling ; biological signal transduction ; Testing ; Tissues ; Body Tissues ; Toxicology ; Virus Diseases ; Viral Diseases ; viral infection ; virus infection ; virus-induced disease ; Measures ; Neurotrophic Tyrosine Kinase Receptor Type 2 ; BDNF Receptor ; BDNF/NT-3 Growth Factors Receptor ; Brain-Derived Neurotrophic Factor Receptor ; GP145-TRKB ; NTRK2 Receptor ; TRKB Tyrosine Kinase ; trkB Receptor ; trkB(gp145) Protein ; Drug Delivery Systems ; Drug Delivery ; Brain-Derived Neurotrophic Factor ; BDNF ; Catalytic Antibodies ; abzyme ; Injury ; injuries ; base ; improved ; Acute ; Chronic ; Clinical ; Phase ; Variant ; Variation ; Biological ; Receptor Protein-Tyrosine Kinases ; PTK Receptors ; Receptor Tyrosine Kinase Gene ; Transmembrane Receptor Protein Tyrosine Kinase ; Tyrosine Kinase Linked Receptors ; Tyrosine Kinase Receptors ; TMEV ; Mouse Polioviruses ; Murine Polioviruses ; Theiler Murine Encephalomyelitis Virus ; Theiler's Virus ; Theiler's encephalomyelitis virus ; Bispecific Antibodies ; Bi-specific antibodies ; Bifunctional Antibodies ; bsAb ; disability ; Individual ; nonhuman primate ; non-human primate ; Recovery ; Agonist ; Brain Injuries ; Acquired brain injury ; brain damage ; brain-injured ; Antibody Therapy ; antibody based therapies ; antibody treatment ; antibody-based therapeutics ; antibody-based treatment ; Collaborations ; Therapeutic ; Inflammatory ; Reporter ; Event ; Protocol ; Protocols documentation ; Degenerative Neurologic Diseases ; Degenerative Neurologic Disorders ; Nervous System Degenerative Diseases ; Neural Degenerative Diseases ; Neural degenerative Disorders ; Neurodegenerative Diseases ; Neurologic Degenerative Conditions ; degenerative diseases of motor and sensory neurons ; degenerative neurological diseases ; neurodegenerative illness ; Neurodegenerative Disorders ; brain cell ; nerve cell death ; nerve cell loss ; neuron cell death ; neuron cell loss ; neuron death ; neuronal cell death ; neuronal cell loss ; neuronal death ; neuronal loss ; neuron loss ; Animal Models and Related Studies ; model of animal ; model organism ; Animal Model ; treatment planning ; Disease Outcome ; Agreement ; disorder model ; Disease model ; Position ; Positioning Attribute ; neurogenesis ; response ; CNS Nervous System ; Central Nervous System ; Neuraxis ; Molecular Interaction ; Binding ; Pharmaceutical Agent ; Pharmaceuticals ; Pharmacological Substance ; Pharmacologic Substance ; preventing ; prevent ; complement pathway ; Dose ; Data ; in vivo ; Rodent Model ; Validation ; Pathologic ; Monitor ; Molecular ; sex ; Development ; developmental ; neuroinflammation ; neuroinflammatory ; Treatment Efficacy ; intervention efficacy ; therapeutic efficacy ; therapy efficacy ; Outcome ; Synaptic plasticity ; N-terminal ; NH2-terminal ; C-terminal ; Therapeutic antibodies ; treatment effect ; neurotropic ; mouse model ; murine model ; neuronal survival ; humanized antibody ; good laboratory practice ; complement system ; nanobodies ; nanobody ; sdAb ; single domain antibodies ; behavioral study ; behavior study ; murine antibody ; Growth Factor ; Growth Agents ; Growth Substances ; Proteins Growth Factors ; experimental study ; experiment ; experimental research ; synaptic pruning ; pharmacokinetics and pharmacodynamics ; PK/PD ; blood-brain barrier penetration ; BBB penetration ; bloodbrain barrier penetration ; blood-brain barrier permeabilization ; BBB permeabilization ; BBB permeable ; blood-brain barrier permeable ; bloodbrain barrier permeabilization ; bloodbrain barrier permeable ; blood-brain barrier crossing ; BBB crossing ; bloodbrain barrier crossing ; effectiveness testing ;
Phase II
Contract Number: ----------Start Date: 00/00/00 Completed: 00/00/00